Bilgin CÖMERT, Volkan İNAL, Gürhan TAŞKIN, Serkan TAPAN, Levent YAMANEL

Paraoxonase 1 activity and survival in sepsis patients

Background: Sepsis is a state of augmented oxidativestress and diminished antioxidant capacity. High den- sity lipoprotein (HDL) particles were shown to possessantioxidant and anti-inflammatory properties, as wellas Paraoxonase 1 (PON1), which is an enzyme that isalso protective against HDL oxidation. Previous stud- ies suggested a possible role of decreased PON1 activ- ity or HDL levels in sepsis patients. Aims: The present study was designed to test a hypoth- esis that higher PON1 activity and HDL-cholesterollevels could predict a better survival in sepsis patients. Study Design: Observational study. Methods: Venous blood samples were collected fromsepsis patients for HDL-cholesterol levels, PON1 ac- tivity and cytokine assays (TNF-α and IL-6) and AcutePhysiologic and Chronic Health Evaluation II (APACHEII) scores were calculated in order to weight patientsdisease severity on the day of sepsis diagnosis. Patientswere followed-up until the 28th day for any cause intra- hospital mortality. Data were statistically analyzed foreffects of study parameters on patients survival. Results: In total, 85 patients with sepsis were includedin the study. The mean age was 65.2±17.9 years and48 were male; at the end of the 28-day follow-up pe- riod, 46 survived. TNF-α (86.9±10.5 vs 118.6±16.4)and IL-6 levels (906.7±82.7 vs 1323.1±54.3) were sig-nificantly higher in non-survivors, while PON1 activity(140.7±42.3 vs 66.7±46.6) and HDL-cholesterol lev-els (43.6±8.1 vs 34.5±8.9) were significantly higher insurvivors (p

PDF

___

1. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013;41:580-637. [CrossRef]
2. Galley HF. Oxidative stress and mitochondrial dysfunction in sepsis. Br J Anaesth 2011;107:57-64. [CrossRef]
3. Pinsky MR. Dysregulation of the immune response in severe sepsis. Am J Med Sci 2004;328:220-9. [CrossRef]
4. Andrades ME, Ritter C, Dal-Pizzol F. The role of free radicals in sepsis development. Front Biosci (Elite Ed) 2009;1:277-87.
5. Draganov D, Teiber J, Watson C, Bisgaier C, Nemzek J, Remick D, et al. PON1 and oxidative stress in human sepsis and an animal model of sepsis. Adv Exp Med Biol 2010;660:89-97. [CrossRef]
6. Chien JY, Jerng JS, Yu CJ, Yang PC. Low serum level of high- density lipoprotein cholesterol is a poor prognostic factor for severe sepsis. Crit Care Med 2005;33:1688-93. [CrossRef]
7. Bojic S, Kotur-Stevuljevic J, Kalezic N, Jelic-Ivanovic Z, Ste- fanovic A, Palibrk I, et al. Low paraoxonase 1 activity pre- dicts mortality in surgical patients with sepsis. Dis Markers 2014;2014:427378. [CrossRef]
8. Li Y, Zhai R, Li H, Mei X, Qiu G. Prognostic value of serum paraoxonase and arylesterase activity in patients with sepsis. J Int Med Res 2013;41:681-7. [CrossRef]
9. Mackness B, Mackness M. Anti-inflammatory properties of para- oxonase-1 in atherosclerosis. Adv Exp Med Biol 2010;660:143- 51. [CrossRef]
10. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res 2004;95:764-72. [CrossRef]
11. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-29. [CrossRef]
12. Huen K, Richter R, Furlong C, Eskenazi B, Holland N. Valida- tion of PON1 enzyme activity assays for longitudinal studies. Clinic Chimic Acta 2009;402:67-74. [CrossRef]
13. Barati M, Nazari MR, TalebiTaher M, Farhadi N. Comparison of Lipid Profile in Septic and Non-Septic Patients. Iran J Clin Infect Dis 2011;6:144-47.
14. Shor R, Wainstein J, Oz D, Boaz M, Matas Z, Fux A, et al. Low HDL levels and the risk of death, sepsis and malignancy. Clin Res Cardiol 2007;97:227-33. [CrossRef]
15. Barlage S, Gnewuch C, Liebisch G, Wolf Z, Audebert FX, Glück T, et al. Changes in HDL-associated apolipo- proteins relate to mortality in human sepsis and correlate to monocyte and platelet activation. Intensive Care Med 2009;35:1877-85. [CrossRef]
16. Costa LG, Furlong CE. Paraoxonase (PON1) in health and dis- ease: basic and clinical aspects. Ch.6. Protective action of HDL- associated PON1 against LDL oxidation, Ch.Ed; Navab M., Hama S.Y., Wagner A.C., Hough G., Watson A.D.), pp. 125-36. Norwell, MA: Kluwer Academic Publishers; 2002.
17. Feingold KR, Memon RA, Moser AH, Grunfeld C. Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis 1998;139:307-15. [CrossRef]
18. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998;394:284-7. [CrossRef]
19. Novak F, Vavrova L, Kodydkova J, Sr FN, Hynkova M, Zak A, et al. Decreased paraoxonase activity in critically ill patients with sepsis. Clin Expe Med 2010;10:21-5. [CrossRef]